Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Oct;265(10):2251-2259.
doi: 10.1007/s00415-018-8984-7. Epub 2018 Jul 27.

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients

Collaborators, Affiliations
Multicenter Study

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients

G Balloy et al. J Neurol. 2018 Oct.

Abstract

Background: Tumefactive demyelinating lesions of the central nervous system can be the initial presentation in various pathological entities [multiple sclerosis (the most common), Balo's concentric sclerosis, Schilder's disease and acute disseminated encephalomyelitis] with overlapping clinical presentation. The aim of our study was to better characterize these patients.

Methods: Eighty-seven patients (62 women and 25 men) from different MS centers in France were studied retrospectively. Inclusion criteria were (1) a first clinical event (2) MRI showing one or more large demyelinating lesions (20 mm or more in diameter) with mass-like features. Patients with a previous demyelinating event (i.e. confirmed multiple sclerosis) were excluded.

Results: Mean age at onset was 26 years. The most common initial symptoms (67% of the patients) were hemiparesis or hemiplegia. Aphasia, headache and cognitive disturbances (i.e. atypical symptoms for demyelinating diseases) were observed in 15, 18 and 15% of patients, respectively. The mean largest diameter of the tumefactive lesions was 26.9 mm, with gadolinium enhancement in 66 patients (81%). Twenty-one patients (24%) had a single tumefactive lesion. During follow-up (median time 5.7 years) 4 patients died, 70 patients improved or remained stable and 12 worsened. 86% of patients received initial corticosteroid treatment, and 73% received disease-modifying therapy subsequently. EDSS at the end of the follow-up was 2.4 ± 2.6 (mean ± SD).

Conclusion: This study provides further evidence that the clinical course of MS presenting with large focal tumor-like lesions does not differ from that of classical relapsing-remitting MS, once the noisy first relapsing occurred.

Keywords: Balo; Demyelinating disease; Multiple sclerosis; Pseudo-tumoral form; Schilder.

PubMed Disclaimer

References

    1. Ann Neurol. 1993 Jan;33(1):18-27 - PubMed
    1. Neurology. 1999 Aug 11;53(3):448-56 - PubMed
    1. Ann Neurol. 2000 Jun;47(6):707-17 - PubMed
    1. Neurology. 1971 Dec;21(12):1179-85 - PubMed
    1. J Neurol. 2013 Aug;260(8):2016-22 - PubMed

Publication types

LinkOut - more resources